EMPA-REG OUTCOME: A decade of transformation from evidence to clinical standard

Czech version

Authors: Daša Skripová
Authors‘ workplace: Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy ARETEUS s. r. o., Trebišov
Published in: Diab Obez 2025; 25(2): 85-88
Category: Reviews

Overview

Ten years ago, the EMPA-REG OUTCOME trial marked a breakthrough in diabetology by demonstrating for the first time that an antidiabetic drug could not only improve glycemic control but also reduce cardiovascular mortality and protect the heart and kidneys. Subsequent trials (EMPEROR, EMPA-KIDNEY) confirmed the efficacy of empagliflozin beyond the diabetic population, extending its impact into cardiology and nephrology. In Slovakia, since 2016, empagliflozin has gradually been incorporated into national recommendations, culminating in the 2025 interdisciplinary consensus on the management of the cardio-renal-metabolic syndrome. Real-world practice shows that its benefits are not just statistical but translate into the tangible prevention of myocardial infarction, dialysis, and hospitalizations. Empagliflozin has a favorable safety profile, is cost-effective, and represents a paradigm shift from glucose-centric care toward a strategy focused on prognosis and quality of life.

Keywords:

empagliflozin – EMPA-REG OUTCOME – cardio-renal-metabolic syndrome

Sources

Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.

Packer M, Anker SD, Butler J et al. [EMPEROR-Reduced Trial Investigators]. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.

Anker SD, Butler J, Filippatos et al. [EMPEROR-Preserved Trial Investigators]. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.

[EMPA-KIDNEY Collaborative Group]. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 389(1): 75–89. Dostupné z DOI: <http://doi: 10.1056/NEJMoa2204233>.

McMurray JJV, Solomon SD, Inzucchi SE et al. [DAPA-HF Trial Committees and Investigators]. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.

Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. [DAPA-CKD Trial Committees and Investigators ]. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

Perkovic V, Jardine MJ, Neal B et al. [CREDENCE Trial Investigators]. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

Cannon CP, Pratley R, Dagogo-Jack S et al. [VERTIS CV Investigators]. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383(15):1425–1435. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2004967>.

Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and the EASD. Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0034>.

[Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group]. KDIGO 2024 Clinical Practice Guideline for the Management of Chronic Kidney Disease. Kidney Int 2024; 105(Suppl 4): S117–S314. Dostupné z DOI: <http://doi/10.1016/j.kint.2023.10.018>.

Schroner Z. Interdisciplinárny dialóg o liečbe kardiometabolického syndrómu (31. 1. –⁠ 1. 2. 2025, Bratislava): správa. Diab Obez 2025; 25(1): 59–62.

Peters AL, Buschur EO, Buse JB et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care 2015; 38(9): 1638–1642. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–1380>.

Wanner C, Inzucchi SE, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.

Baker WL, Smyth LR, Riche DM et al. Effects of sodium–glucose cotransporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Heart Assoc 2014; 8(4): 262–275. Dostupné z DOI: <http://doi: 10.1016/j.jash.2014.01.007>.

Neal B, Perkovic V, Mahaffey KW et al. [CANVAS Program Collaborative Group]. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.

Chou OH, Luo Z, Chung CT et al. Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study. J Am Heart Assoc 2025; 14(11): e034175. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.123.034175>.

Yen FS, Wei JC, Yu TS et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. JAMA Netw Open 2023; 6(12): e2348431.Dostupné z DOI: <http://dx.doi.org/10.1001/jamanetworkopen.2023.48431>.

Balasubramanian P, Wanner C, Ferreira JP et al. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? J Clin Endocrinol Metab 2022; 107(7): e3003-e3007. Dostupné z DOI: <http://dx.doi.org/10.1210/clinem/dgac154>. Erratum in: J Clin Endocrinol Metab 2022; 107(9):e3971. Dostupné z DOI: <http://dx.doi.org/10.1210/clinem/dgac340>.

Wu CY, Iskander C, Wang C et al. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Diabetes Care 2023; 46(2): 297–304. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22–1705>.

Cheung KS, Ng HY, Hui RWH et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Hepatology 2024; 80(4): 916–927. <Dostupné z DOI: http://dx.doi.org/10.1097/HEP.0000000000000855>.

Lai LL, Vethakkan SR, Nik Mustapha NR et al. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 2020; 65(2): 623–631. Dostupné z DOI: <http://dx.doi.org/10.1007/s10620–019–5477–1>.